Skip to content Skip to navigation

Prof. Catherine Lyall

Prof. Catherine Lyall (& Dr Emma King)

Professor of Science and Public Policy

Science, Technology, and Innovation Studies, The University of Edinburgh

Professor of Science and Public Policy, University of Edinburgh.

Catherine is an experienced science policy researcher and evaluator of knowledge exchange and interdisciplinary research activities. 

She has previously served as Deputy Director for both the ESRC Innogen Centre (2007-2012) and the ESRC Genomics Forum (2012-2013). 

Her research seeks to advance an understanding of problems of science and technology policy formation and strategic decision-making by adopting interdisciplinary and practitioner-based perspectives. 

Catherine’s publications include Interdisciplinary Research Journeys (with Ann Bruce, Joyce Tait and Laura Meagher, Bloomsbury Academic, 2011) and The Limits to Governance: The Challenges of Policy Making for the New Life Sciences (edited with Theo Papaioannou and James Smith, Ashgate, 2009). 

In 2013 she co-edited a special section of the journal Science and Public Policy with Isabel Fletcher on Investing in Interdisciplinarity and a special edition of Evidence & Policy with Christine Knight on Knowledge brokers: the role of intermediaries in producing research impact.

Within the Novosang project, Professor Lyall and Dr Emma King's research involves eliciting the views of wider publics towards the introduction of laboratory-derived red blood cells.

This qualitative research is being undertaken using interviews and focus groups with various members of the public, including patients, religious organisations and community groups.

Using these methods entails writing participant information sheets and obtaining consent, recruiting participants (often through gate-keeping organisations) and carrying out data collection. Voice recordings of interviews and focus groups are then transcribed, and analysed using specialist software.

Preliminary findings indicate that participants are generally positive about the introduction of the Novosang product.